EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors ; volume:20 ; number:1 ; day:28 ; month:4 ; year:2020 ; pages:1-13 ; date:12.2020
BMC cancer ; 20, Heft 1 (28.4.2020), 1-13, 12.2020
- Creator
-
Chiang, Anne C.
Fernandes, Ancilla W.
Pavilack, Melissa
Wu, Jennifer W.
Laliberté, François
Duh, Mei Sheng
Chehab, Nabil
Subramanian, Janakiraman
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-020-06826-0
- URN
-
urn:nbn:de:101:1-2020070823514399847886
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chiang, Anne C.
- Fernandes, Ancilla W.
- Pavilack, Melissa
- Wu, Jennifer W.
- Laliberté, François
- Duh, Mei Sheng
- Chehab, Nabil
- Subramanian, Janakiraman
- SpringerLink (Online service)
Other Objects (12)
Second-generation inhibitors of Bruton tyrosine kinase
Neue Inhibitoren der Epidermal Growth Factor related Tyrosine Phosphokinase (EGFrTK), CARN 79079-06-4
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005)
Is Turkey Progressing?
Veränderung des Epidermal Growth Factor Receptors (EGFR) bei Sarkomen
Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations
![Is Volapük progressing? : [Kopftitel]](https://iiif.deutsche-digitale-bibliothek.de/image/2/8be7e498-73fb-459e-b546-97f7ae30c2ce/full/!306,450/0/default.jpg)
Is Volapük progressing? : [Kopftitel]
Second-generation inhibitors of Bruton tyrosine kinase
Neue Inhibitoren der Epidermal Growth Factor related Tyrosine Phosphokinase (EGFrTK), CARN 79079-06-4
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005)
Is Turkey Progressing?
Veränderung des Epidermal Growth Factor Receptors (EGFR) bei Sarkomen
Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations
Is Volapük progressing? : [Kopftitel]
Second-generation inhibitors of Bruton tyrosine kinase
Neue Inhibitoren der Epidermal Growth Factor related Tyrosine Phosphokinase (EGFrTK), CARN 79079-06-4
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005)
Is Turkey Progressing?
Veränderung des Epidermal Growth Factor Receptors (EGFR) bei Sarkomen
Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations